C. Cebotaru

Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases

In vitro and In vivo Radiosensitization with AZD6244 (ARRY-142886), an Inhibitor of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase 1/2 Kinase

Development of siRNA Payloads to Target KRAS -Mutant Cancer

Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment

Cancer statistics, 2022

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

Head and neck squamous cell carcinoma

Cancer Statistics, 2021

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

Combined modality therapy with TRAIL or agonistic death receptor antibodies

MEK in cancer and cancer therapy

A view on drug resistance in cancer

Hepatocellular carcinoma

The Levels of Evidence and Their Role in Evidence-Based Medicine

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning

Primary breast lymphoma in a patient with silicone breast implants: a case report and review of the literature

A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

RAS-targeted therapies: is the undruggable drugged?

A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Lung cancer: current therapies and new targeted treatments

Targeting apoptosis in cancer therapy

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

Broadening horizons: the role of ferroptosis in cancer

Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma

PROTAC targeted protein degraders: the past is prologue

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer

Pancreatic Cancer

Prospects for MEK inhibitors for treating cancer

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma

Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma

The MAPK pathway across different malignancies: A new perspective

In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism

Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer

Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges

Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas

Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives

Copper induces cell death by targeting lipoylated TCA cycle proteins

Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

Primary breast lymphoma: a report of 20 cases

A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

P-209 Comparison of three cisplatin (P) doublets — Gemcitabine/P (GP), paclitaxel/P (TP), etoposide/P (EP) in advanced (stage IIIB and IV) non-small cell lung cancer (NSCLC)

A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC.

A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Angiopoietin-2 as a predictive marker for clinical outcomes.

Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC)

A randomized phase IItrial of mapatumumab, a TRAIL R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC